Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Quoin Pharmaceuticals ( (QNRX) ) has issued an update.
On May 29, 2025, Quoin Pharmaceuticals Ltd.’s Compensation Committee approved 2024 annual cash bonuses for Dr. Michael Myers and Ms. Denise Carter, amounting to $331,238 and $264,640 respectively. These bonuses align with the CEO and COO Compensation Programs approved at the company’s annual meeting on December 5, 2024, reflecting the company’s commitment to rewarding its executive leadership.
The most recent analyst rating on (QNRX) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Quoin Pharmaceuticals stock, see the QNRX Stock Forecast page.
Spark’s Take on QNRX Stock
According to Spark, TipRanks’ AI Analyst, QNRX is a Underperform.
Quoin Pharmaceuticals is in a challenging financial position with no revenue generation and high reliance on external financing. The technical analysis indicates a bearish trend, though some technical indicators suggest the stock may be oversold. Valuation metrics reflect the company’s lack of profitability. The combination of these factors results in a low stock score, highlighting significant risks to investors.
To see Spark’s full report on QNRX stock, click here.
More about Quoin Pharmaceuticals
Average Trading Volume: 287,284
Technical Sentiment Signal: Sell
Current Market Cap: $5.14M
See more data about QNRX stock on TipRanks’ Stock Analysis page.